GlassScriptPhysician profile
Eunyoung Cho
NPI 1104405901
$4,479.71
in general payments reported to CMS, 2019-2025
26 companies · $924 in 2025
The $924 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $886 · 2022: $564 · 2023: $1,653 · 2024: $453 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,626 · Education: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,625.74 |
| Education | $403.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $604.80 | 2022-2025 | Xospata, Padcev, Xtandi |
| Seagen INC. | $560.38 | 2021-2023 | Adcetris |
| E.R. Squibb & Sons, L.L.C. | $288.05 | 2025 | Opdivo |
| Daiichi Sankyo INC. | $268.43 | 2021-2025 | Enhertu, Datroway |
| Pfizer INC. | $265.57 | 2021-2025 | |
| Mirati Therapeutics, INC. | $253.78 | 2023 | Krazati |
| Incyte Corporation | $250.25 | 2024-2025 | Pemazyre, Monjuvi, Jakafi |
| Genzyme Corporation | $240.56 | 2021 | |
| Genentech USA, INC. | $164.46 | 2022-2025 | Phesgo |
| Alexion Pharmaceuticals, INC. | $147.82 | 2022-2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $129.63 | 2023 | |
| Celgene Corporation | $128.07 | 2021-2023 | Pomalyst |
| Glaxosmithkline, LLC. | $125.00 | 2025 | Jemperli |
| Genmab U.S., INC. | $125.00 | 2023 | Tivdak |
| Eisai INC. | $124.99 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $124.98 | 2023 | |
| Dova Pharmaceuticals | $120.94 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $117.37 | 2023 | Imbruvica |
| Janssen Biotech, INC. | $111.11 | 2023 | Imbruvica |
| Amgen INC. | $99.00 | 2021 | |
| Merck Sharp & Dohme LLC | $83.23 | 2023-2025 | Keytruda, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $58.32 | 2021-2025 | Lynparza |
| Novartis Pharmaceuticals Corporation | $33.14 | 2025 | |
| Sumitomo Pharma America, INC. | $22.32 | 2023 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $20.01 | 2021 | |
| Karyopharm Therapeutics INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eunyoung Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.